FDA Approves Inhaled Insulin for Pediatric Diabetes Treatment

The U.S. Food and Drug Administration (FDA) has approved Afrezza, an inhaled insulin, for use in children and adolescents aged 6 and older with type 1 and type 2 diabetes. This approval expands the treatment options available for pediatric diabetes management.

Inhaled insulin offers a needle-free alternative to traditional injected mealtime insulin. This may address challenges associated with adherence, social stigma, and the physical discomfort of multiple daily injections, particularly in younger patients.

While inhaled insulin provides metabolic flexibility and rapid

While inhaled insulin provides metabolic flexibility and rapid action, it does not replace the need for other insulin delivery systems or long-acting insulin. Healthcare providers will need to assess individual patient needs to determine the most appropriate treatment regimen.

Access to this new treatment may present financial considerations for some families, as indicated by current out-of-pocket payment requirements for trial participants.